SCHEMBL4237606

SCHEMBL4237606

O=C(OCC1C2CN(Cc3ccccc3)CC12)N(Cc1ccccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 7/20 0.48
CHRM1 P11229 7/20 0.48
CHRM3 P20309 7/20 0.48
ACHE P22303 4/20 0.46
BCHE P06276 3/20 0.46
PKM P14618 1/20 0.44
NPC1 O15118 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GLA P06280 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
PAX8 Q06710 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FUCA1 P04066 2/20 0.43
S1PR1 P21453 1/20 0.41
S1PR5 Q9H228 1/20 0.41
OPRM1 P35372 1/20 0.40
SIGMAR1 Q99720 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4245563 0.90 ACHE (0.49) CHRM2CHRM1CHRM3ACHEBCHE
SCHEMBL4248347 0.88 CHRM2 (0.52) CHRM2CHRM1CHRM3ACHEBCHE
SCHEMBL4238211 0.84 CHRM2 (0.47) CHRM2CHRM1CHRM3ACHEBCHE
SCHEMBL4241506 0.83 CHRM2 (0.48) CHRM2CHRM1CHRM3ACHEBCHE
SCHEMBL19971617 0.83 BCHE (0.55) ACHEBCHEFUCA1S1PR1S1PR5
SCHEMBL19971616 0.83 BCHE (0.55) ACHEBCHEFUCA1S1PR1S1PR5
SCHEMBL19971615 0.83 BCHE (0.55) ACHEBCHEFUCA1S1PR1S1PR5
SCHEMBL4237658 0.81 CHRM2 (0.46) CHRM2CHRM1CHRM3NPC1ALDH1A1
SCHEMBL4237271 0.81 CHRM2 (0.46) CHRM2CHRM1CHRM3ACHEBCHE
SCHEMBL4244214 0.81 KCNH2 (0.45) CHRM2CHRM1CHRM3ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US claimed
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US disclosed
EP-1904446-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-04-02 EP disclosed
WO-2007007282-A2 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012116-A1 Muscarinic Receptor Antagonists CHRM3, CHRM2, CHRM5 CHRM2 2/4885CHRM1 5/4885CHRM3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.